Published in Ann Oncol on January 01, 2005
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res (2009) 1.64
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol (2011) 1.57
Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor. World J Surg Oncol (2013) 1.54
Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol (2010) 1.47
Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer (2009) 1.25
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics (2008) 1.13
Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. Oncotarget (2016) 1.11
Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor. Pharm Res (2008) 1.07
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer (2007) 1.06
Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One (2011) 1.01
Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract (2012) 1.01
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol (2013) 0.97
Paclitaxel inhibits growth, migration and collagen production of human Tenon's fibroblasts--potential use in drug-eluting glaucoma drainage devices. Graefes Arch Clin Exp Ophthalmol (2009) 0.95
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol (2011) 0.95
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer (2008) 0.93
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
Ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients. BMC Cancer (2012) 0.91
LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. BMC Cancer (2012) 0.91
Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag (2009) 0.90
Management of peritoneal carcinomatosis from colorectal cancer. Semin Oncol (2011) 0.87
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer (2008) 0.87
Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Transl Oncol (2012) 0.86
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res (2012) 0.86
High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. PLoS One (2013) 0.86
Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Ther Adv Med Oncol (2014) 0.85
Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol. BMC Cancer (2007) 0.85
Chemotherapy: Current drugs still have potential in advanced ovarian cancer. Nat Rev Clin Oncol (2010) 0.84
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer (2010) 0.83
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health (2013) 0.82
Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter? Br J Cancer (2013) 0.82
The prognostic significance of Jun transcription factors in ovarian cancer. J Cancer Res Clin Oncol (2013) 0.82
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecol Oncol (2006) 0.81
Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel. J Ovarian Res (2012) 0.81
Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia (2010) 0.81
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol (2008) 0.80
Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy. Cancer Microenviron (2013) 0.78
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol (2010) 0.78
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother (2013) 0.78
Doublet chemotherapy in the elderly patient with ovarian cancer. Oncologist (2012) 0.78
Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer. Int J Mol Sci (2014) 0.78
Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy. Oncotarget (2016) 0.77
Thoracic metastasis in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery. J Gynecol Oncol (2011) 0.76
Are there candidates for high-dose chemotherapy in ovarian carcinoma? J Exp Clin Cancer Res (2012) 0.76
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. Br J Clin Pharmacol (2015) 0.76
First-Line Chemotherapy for Ovarian Cancer: Inferences From Recent Studies. Oncologist (2016) 0.75
Clinical course of patients treated for advanced ovarian carcinoma without surgical intervention. PLoS One (2013) 0.75
Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin. Gynecol Oncol (2009) 0.75
Chemotherapy for Elderly Ovarian Cancer Patients. Gynecol Obstet (Sunnyvale) (2016) 0.75
Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer. J Obstet Gynaecol India (2013) 0.75
Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin. World J Surg Oncol (2016) 0.75
Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France. Clin Epidemiol (2015) 0.75
Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer. Cancer Microenviron (2014) 0.75
Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model. J Control Release (2017) 0.75
[Therapeutic standards for ovarian cancer]. Pathologe (2007) 0.75
Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging (2001) 25.22
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Temporal autocorrelation in univariate linear modeling of FMRI data. Neuroimage (2001) 12.61
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet (2008) 8.12
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol (2000) 7.94
The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ (2007) 7.74
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature (1993) 7.11
Fluorescent antibody localization of myosin in the cytoplasm, cleavage furrow, and mitotic spindle of human cells. J Cell Biol (1976) 6.94
Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst (1999) 6.51
Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med (2001) 6.01
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 5.39
Report of a National Workshop on Screening for Cancer of the Cervix. CMAJ (1991) 5.37
Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer (1990) 5.34
FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet (2000) 5.33
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell (1986) 5.22
The epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing hospital-acquired infections. Department of Health (England). J Hosp Infect (2001) 4.95
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Microtubules: evidence for 13 protofilaments. J Cell Biol (1973) 4.91
LasR of Pseudomonas aeruginosa is a transcriptional activator of the alkaline protease gene (apr) and an enhancer of exotoxin A expression. Infect Immun (1993) 4.90
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 4.76
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995) 4.75
Microtubules and the endoplasmic reticulum are highly interdependent structures. J Cell Biol (1986) 4.59
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med (1995) 4.56
Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol (2001) 4.54
School-based programs to reduce sexual risk behaviors: a review of effectiveness. Public Health Rep (1994) 4.50
Activity-dependent action potential invasion and calcium influx into hippocampal CA1 dendrites. Science (1995) 4.29
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet (2001) 3.99
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
Correlations between T-cell specificity and the structure of the antigen receptor. Nature (1986) 3.83
Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med (1995) 3.76
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol (2009) 3.63
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
School-based screening for tuberculous infection. A cost-benefit analysis. JAMA (1995) 3.47
The precautionary principle in environmental science. Environ Health Perspect (2001) 3.47
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33
Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 3.25
Precancerous changes in the cervix and risk of subsequent preterm birth. BJOG (2006) 3.25
Replication and plaque formation of mouse hepatitis virus (MHV-2) in mouse cell line DBT culture. Arch Gesamte Virusforsch (1974) 3.24
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology (1994) 3.22
Are amyotrophic lateral sclerosis patients cognitively normal? Neurology (2003) 3.21
Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol (2002) 2.99
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol (2002) 2.86
Centriole ciliation is related to quiescence and DNA synthesis in 3T3 cells. Cell (1979) 2.84
Calcium action potentials restricted to distal apical dendrites of rat neocortical pyramidal neurons. J Physiol (1997) 2.77
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
Early sleep triggers memory for early visual discrimination skills. Nat Neurosci (2000) 2.74
The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum (1998) 2.74
A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol (1997) 2.71
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol (2000) 2.70
Breast cancer among black and white women in the 1980s. Changing patterns in the United States by race, age, and extent of disease. Cancer (1993) 2.70
Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol (2001) 2.69
Inflammatory mediators in acute pancreatitis. J Pathol (2000) 2.66
Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA (1991) 2.64
Public-sector patents on human DNA. Nature (1997) 2.63
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 2.62
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab (2001) 2.61
Simultaneous localization of myosin and tubulin in human tissue culture cells by double antibody staining. J Cell Biol (1978) 2.59
Modern methods of searching the medical literature. Med J Aust (1992) 2.58
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst (1989) 2.58
Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis (2009) 2.55
Two distinct mechanisms for redistribution of lymphocyte surface macromolecules. I. Relationship to cytoplasmic myosin. J Cell Biol (1978) 2.54
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol (2010) 2.54
Gastric cancer: epidemiology, pathology and treatment. Ann Oncol (2003) 2.53
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A (1986) 2.51
Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 2.47
Characterization and localization of myosin in the brush border of intestinal epithelial cells. J Cell Biol (1978) 2.47
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res (2000) 2.43
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest (1984) 2.43
Glutamate receptors regulate actin-based plasticity in dendritic spines. Nat Neurosci (2000) 2.41
Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant (1997) 2.39
Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol (1994) 2.38
FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet (1999) 2.36
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer (2008) 2.35
A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol (1997) 2.35
Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res (2002) 2.32
High actin concentrations in brain dendritic spines and postsynaptic densities. Proc Natl Acad Sci U S A (1982) 2.31
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented. BMJ (2003) 2.30
Haptoglobin phenotype and diabetic nephropathy. Diabetologia (2001) 2.27
Airway smooth muscle, tidal stretches, and dynamically determined contractile states. Am J Respir Crit Care Med (1997) 2.26
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer (2011) 2.24
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer (2006) 2.23